The purpose of this review is to summarise the main pharmacological and clinical characteristics of paritaprevir/ ritonavir/ombitasvir, and dasabuvir (VIEKIRA PAK), which is an orally-administered interferon-sparing anti-viral drug regimen for use in the treatment of chronic hepatitis C viral infection. In Australia, paritaprevir/ ritonavir/ombitasvir, and dasabuvir is registered with the Therapeutic Goods Administration (TGA) and is in the reimbursement process.
Please login below to download this issue (PDF)